RegeneronREGN

NASDAQ · USA · Segment 3 of 8 in the Medicine, pharma & life science value chain: Biotech & innovation

American biotech company focused on antibody-based medicines in ophthalmology, immunology and oncology.

Biotech & innovation: Innovation-driven biotech companies focused on novel treatment modalities.

Key metrics

Market cap

$69.9B

Price

$663.86

Today

−0.6%

Return YTD

−13.5%

Return 1Y

+20.9%

P/E

15.8

P/S

4.7

P/B

2.2

Data as of 2026-07-10 · updates daily after U.S. close

Theme exposure

BiotechImmunologyOncology

In the value chain

Products & services

Ophthalmology (Eylea)
Immunology (Dupixent, with Sanofi)
Oncology

Competitors

Risks

Competition on Eylea
Dependence on partner products

Same segment: Biotech & innovation

AmgenAMGN Gilead SciencesGILD Vertex PharmaceuticalsVRTX Alnylam PharmaceuticalsALNY ModernaMRNA BiogenBIIB IncyteINCY United TherapeuticsUTHR

See where Regeneron sits in the full Medicine, pharma & life science map — every segment from upstream suppliers to end markets, with daily metrics.Open the Life science value chain →